J Ethnopharmacol:清肺口服液通过Akt信号通路促进脂肪酸依赖性M1/M2巨噬细胞极化,减轻RSV诱导的肺部炎症

2022-08-22 紫菀款冬 MedSci原创

通过脂肪酸依赖性巨噬细胞极化研究清肺口服液(QF)是否能够抑制呼吸道合胞病毒(RSV)诱导的小鼠模型肺部炎症。

背景:呼吸道合胞病毒(RSV)是导致婴幼儿和老年人下呼吸道疾病的常见病原体,目前尚无疫苗接种。清肺口服液(QF)是一种中药配方,临床证明具有抗炎作用

目的:该研究通过脂肪酸依赖性巨噬细胞极化研究QF是否能够抑制RSV诱导的小鼠模型肺部炎症。

方法:在RSV感染后,BALB/c小鼠连续4天灌胃低、中、高剂量QF。使用H&E染色和细胞因子分析评估肺部炎症状态。使用超高效液相色谱/串联质谱(UPLC-MS/MS)分析QF和脂肪酸代谢的活性成分。通过网络药理学和分子对接研究发现脂质代谢相关途径

Western印迹分析用于测定ATP柠檬酸裂解酶(ACLY)、过氧化物酶体增殖激活受体α(PPAR)、Akt蛋白激酶B及其在Akt信号中的磷酸化形式的水平。流式细胞术用于定量巨噬细胞亚型(M1/M2)的数量免疫组织化学用于检测诱导型一氧化氮合酶(iNOS)和精氨酸酶-1(Arg-1)的表达。

结果:在RSV感染小鼠的肺组织中,QF抑制促炎蛋白如白细胞介素-1β(IL-1β)、肿瘤坏死因子α(TNF-α)和白细胞介素6(IL-6)的转录,同时增加抗炎因子如白细胞介素-10(IL-10)的水平。

由Akt信号传导介导的代谢酶活性的改变与QF显著减少肺脂肪酸积累有关。QF处理后发现低ACLY表达和高PPAR表达,表明这两种酶是Akt信号的下游靶点,分别控制脂肪酸合成(FAS)和脂肪酸氧化(FAO)

脂肪酸代谢的重新编程导致巨噬细胞从M1极化为M2,iNOS表达较低,Arg-1表达较高。此外,应用Akt激动剂(SC-79)通过增加FAS和减少巨噬细胞极化来降低QF的抗炎作用

结论:QF抑制Akt介导的FAS,极化M1至M2巨噬细胞,具有抗炎作用

 

文献来源:

An L, Lu M, Xu W, et al. Qingfei oral liquid alleviates RSV-induced lung inflammation by promoting fatty-acid-dependent M1/M2 macrophage polarization via the Akt signaling pathway [published online ahead of print, 2022 Aug 12]. J Ethnopharmacol. 2022;115637. doi:10.1016/j.jep.2022.115637

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-01-12 yb6560
  4. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-05-20 songbq
  5. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-02-08 xfpan20
  6. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2023-07-24 jj000001
  7. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
    2022-08-20 feather81
  9. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1788498, encodeId=2e1e1e8849892, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Thu May 04 23:46:25 CST 2023, time=2023-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1940607, encodeId=487a194060e77, content=<a href='/topic/show?id=e1cf82352c7' target=_blank style='color:#2F92EE;'>#肺部炎症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82352, encryptionId=e1cf82352c7, topicName=肺部炎症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfa576, createdName=wfang545, createdTime=Wed Oct 19 02:46:25 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996504, encodeId=86d31996504ae, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Thu Jan 12 10:46:25 CST 2023, time=2023-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981160, encodeId=57631981160a2, content=<a href='/topic/show?id=1bbe38225a4' target=_blank style='color:#2F92EE;'>#口服液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38225, encryptionId=1bbe38225a4, topicName=口服液)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=856b247, createdName=songbq, createdTime=Sat May 20 18:46:25 CST 2023, time=2023-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656209, encodeId=3cdf165620936, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Wed Feb 08 10:46:25 CST 2023, time=2023-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787823, encodeId=904f1e878235c, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Mon Jul 24 15:46:25 CST 2023, time=2023-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908732, encodeId=87911908e329f, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Fri Jun 09 05:46:25 CST 2023, time=2023-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1507519, encodeId=3aea150e519bf, content=<a href='/topic/show?id=d33f15e143f' target=_blank style='color:#2F92EE;'>#RSV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15714, encryptionId=d33f15e143f, topicName=RSV)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f939898798, createdName=feather81, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1539813, encodeId=1f421539813e6, content=<a href='/topic/show?id=c61a2e315da' target=_blank style='color:#2F92EE;'>#信号通路#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27315, encryptionId=c61a2e315da, topicName=信号通路)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b12d13147749, createdName=wgx310, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597885, encodeId=bc21159e8850b, content=<a href='/topic/show?id=b1e3e7926ba' target=_blank style='color:#2F92EE;'>#细胞极化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77926, encryptionId=b1e3e7926ba, topicName=细胞极化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e318558301, createdName=tastas, createdTime=Sat Aug 20 14:46:25 CST 2022, time=2022-08-20, status=1, ipAttribution=)]

相关资讯

呼吸道合胞病毒(RSV)抗体Nirsevimab,试验取得积极结果

在 RSV 季节之前单次注射 nirsevimab 可保护健康的晚期早产儿和足月儿童免受 RSV 相关下呼吸道感染的威胁。

Lancet respir med:ALX-0171用于呼吸道合胞病毒感染的治疗

ALX-0171可降低呼吸道合胞病毒感染患儿体内病毒载量,但对临床病程无显著作用

Pediatrics:新冠大流行期间儿童的急性呼吸道疾病

2020 年 3 月至 4 月期间,美国 7 个城市的 ARI 病例以及儿童 RSV 和流感的比例迅速下降,这可能归因于针对新冠病毒采取的社区隔离措施。

NEJM:孕妇接种合胞病毒疫苗可以预防婴儿感染呼吸道合胞病毒

全世界每年约有118,200名儿童死于呼吸道合胞病毒(RSV),其中约一半发生在6个月以下婴儿中,绝大多数发生在发展中国家。在美国,RSV是婴儿住院的常见原因,估计每年RSV肺炎发病率超过2000例/

IORV:成人非免疫缺陷患者呼吸道合胞病毒相关急性呼吸系统疾病

呼吸道合胞病毒(RSV)是一种日益常见的导致成人非免疫缺陷患者呼吸道疾病的原因。